EraCal Therapeutics: EraCal closes oversubscribed seed round
A consortium of investors comprising Bernina BioInvest, Redalpine, Life Sciences Fund and private investors have joined hands to support EraCal in bringing its anti-obesity medicines on the market. The funds from the oversubscribed seed round will allow EraCal to kick-off pre-clinical studies.
Read full article »
EraCal Therapeutics is a biotechnology company that develops and commercializes drugs to treat anti-obesity problems.
Read more